MA30766B1 - Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide - Google Patents

Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide

Info

Publication number
MA30766B1
MA30766B1 MA31733A MA31733A MA30766B1 MA 30766 B1 MA30766 B1 MA 30766B1 MA 31733 A MA31733 A MA 31733A MA 31733 A MA31733 A MA 31733A MA 30766 B1 MA30766 B1 MA 30766B1
Authority
MA
Morocco
Prior art keywords
dosage forms
pharmaceutical dosage
opioid analgesic
oral pharmaceutical
forms anti
Prior art date
Application number
MA31733A
Other languages
English (en)
Inventor
Richard Owen Mannion
Edward Patrick O'donnell
William Henry Mckenna
Haiyong Hugh Huang
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30766(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of MA30766B1 publication Critical patent/MA30766B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B7/00—Mixing; Kneading
    • B29B7/02—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B7/00—Mixing; Kneading
    • B29B7/80—Component parts, details or accessories; Auxiliary operations
    • B29B7/88—Adding charges, i.e. additives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/04—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
    • B29C35/045—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/16—Cooling
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C37/00—Component parts, details, accessories or auxiliary operations, not covered by group B29C33/00 or B29C35/00
    • B29C37/0025—Applying surface layers, e.g. coatings, decorative layers, printed layers, to articles during shaping, e.g. in-mould printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/02—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/32—Component parts, details or accessories; Auxiliary operations
    • B29C43/52—Heating or cooling
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
    • B29C71/009—After-treatment of articles without altering their shape; Apparatus therefor using gases without chemical reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/04—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
    • B29C35/045—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
    • B29C2035/046—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames dried air
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/16—Cooling
    • B29C2035/1658—Cooling using gas
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02—Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25—Solid
    • B29K2105/251—Particles, powder or granules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0088—Molecular weight
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Thermal Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Plasma & Fusion (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION CONCERNE DES FORMES POSOLOGIQUES PHARMACEUTIQUES, PAR EXEMPLE UNE FORME POSOLOGIQUE INVIOLABLE COMPRENANT UN ANALGÉSIQUE OPIOÏDE, ET LEURS PROCÉDÉS DE FABRICATION, LEURS UTILISATIONS ET DES PROCÉDÉS DE TRAITEMENT PAR CES FORMES POSOLOGIQUES.
MA31733A 2006-08-25 2009-03-24 Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide MA30766B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84024406P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
MA30766B1 true MA30766B1 (fr) 2009-10-01

Family

ID=38754532

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31733A MA30766B1 (fr) 2006-08-25 2009-03-24 Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide

Country Status (41)

Country Link
US (69) US8894987B2 (fr)
EP (11) EP2080514B1 (fr)
JP (8) JP5069300B2 (fr)
KR (8) KR101514388B1 (fr)
CN (9) CN103861111B (fr)
AP (1) AP2009004770A0 (fr)
AR (4) AR062511A1 (fr)
AT (5) ATE489954T1 (fr)
AU (1) AU2007287341B2 (fr)
BR (2) BR122016004010B8 (fr)
CA (2) CA2661573C (fr)
CL (3) CL2007002485A1 (fr)
CO (1) CO6160317A2 (fr)
CR (2) CR10691A (fr)
CY (7) CY1110573T1 (fr)
DE (5) DE602007010974D1 (fr)
DK (11) DK2343071T3 (fr)
DO (2) DOP2009000026A (fr)
EA (3) EA023807B1 (fr)
ES (11) ES2411695T3 (fr)
GT (2) GT200900023BA (fr)
HR (11) HRP20090688T1 (fr)
IL (10) IL197214A (fr)
IN (1) IN2015DN01813A (fr)
JO (2) JO2858B1 (fr)
MA (1) MA30766B1 (fr)
ME (7) ME01339B (fr)
MX (2) MX2009002023A (fr)
MY (3) MY153092A (fr)
NZ (3) NZ608651A (fr)
PE (5) PE20150340A1 (fr)
PL (11) PL2311459T3 (fr)
PT (11) PT2343071E (fr)
RS (11) RS51664B (fr)
SA (1) SA07280459B1 (fr)
SI (11) SI2292229T1 (fr)
TN (1) TN2009000059A1 (fr)
TW (1) TWI341213B (fr)
UA (2) UA96306C2 (fr)
WO (1) WO2008023261A1 (fr)
ZA (1) ZA200900755B (fr)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme de liberation a base de polymere
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2218448B1 (fr) 2002-12-13 2015-09-23 Durect Corporation Forme d'administration orale de medicaments comprenant un vehicule liquide de haute viscosite
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ563846A (en) * 2005-06-03 2010-03-26 Egalet As A drug delivery system for delivering active substances dispersed in a dispersion medium
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
CN105534936B (zh) 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
EP2067471B1 (fr) 2007-12-06 2018-02-14 Durect Corporation Formes orales de dosage pharmaceutique
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
WO2009114648A1 (fr) * 2008-03-11 2009-09-17 Depomed Inc. Formes médicamenteuses à libération étendue de rétention gastrique comprenant des combinaisons d'un analgésique non opioïde et d'un analgésique opioïde
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
CN102159193B (zh) * 2008-09-18 2015-09-16 普渡制药公司 包含聚(ε-己内酯)的药物剂型
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2379111B1 (fr) 2008-12-12 2013-03-20 Paladin Labs Inc. Formulations médicamenteuses narcotiques avec un potentiel d'abus réduit
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
ES2607209T3 (es) 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
WO2010127100A1 (fr) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprenant un antihistaminique, un antitussif et un décongestionnant dans des formulations à libération prolongée
US20100280059A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
EP3064064A1 (fr) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Procédés et compositions de dissuasion d'abus
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
SG184523A1 (en) 2010-05-10 2012-11-29 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
WO2011141490A1 (fr) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combinaison de granules chargés de principe actif et de principes actifs supplémentaires
AU2011267474B2 (en) 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
CA2808219C (fr) 2010-09-02 2019-05-14 Gruenenthal Gmbh Forme pharmaceutique inviolable comportant un sel inorganique
WO2012028318A1 (fr) 2010-09-02 2012-03-08 Grünenthal GmbH Forme pharmaceutique inviolable comportant un polymère anionique
EP2651399A2 (fr) 2010-12-13 2013-10-23 Purdue Pharma LP Formes pharmaceutiques permettant une libération contrôlée
CN104856967A (zh) * 2010-12-22 2015-08-26 普渡制药公司 包覆的抗篡改控制释放剂型
PL2826467T3 (pl) 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
CN103547259A (zh) * 2011-03-25 2014-01-29 普渡制药公司 控制释放药物剂型
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
AT511581A1 (de) 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
US20140341984A1 (en) * 2011-09-16 2014-11-20 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2012310251B2 (en) * 2011-09-16 2016-01-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
WO2013057570A2 (fr) * 2011-10-18 2013-04-25 Purdue Pharma L.P. Formulations de polymère acrylique
KR20140096062A (ko) 2011-11-17 2014-08-04 그뤼넨탈 게엠베하 약리학적 활성 성분, 오피오이드 길항제 및/또는 혐오제, 폴리알킬렌 옥사이드 및 음이온성 중합체를 포함하는 탬퍼-저항성 경구 약제학적 투여형
US20150224097A1 (en) * 2011-11-22 2015-08-13 Watson Pharmaceuticals, Inc. Immediate Release Abuse Deterrent Tablet
ES2603278T3 (es) * 2011-12-09 2017-02-24 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (epsilon-caprolactona) y óxido de polietileno
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
WO2013158814A1 (fr) 2012-04-18 2013-10-24 Mallinckrodt Llc Compositions pharmaceutiques dissuasives d'abus, à libération immédiate
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP2015521988A (ja) * 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
US9730885B2 (en) * 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CN104968333B (zh) 2012-11-30 2018-07-10 阿库拉制药公司 活性药物成分的自调节释放
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
BR112015021002B8 (pt) 2013-03-15 2023-03-28 Mallinckrodt Llc Forma de dosagem sólida farmacêutica compreendendo um ingrediente farmacêutico ativo
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
CA2905131A1 (fr) 2013-03-15 2014-09-18 Durect Corporation Compositions ayant un agent de modification rheologique pour reduire une variabilite de dissolution
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014273227B2 (en) * 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
JP6232135B2 (ja) 2013-11-13 2017-11-15 ユーロ−セルティーク エス．エイ． 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2938699A1 (fr) 2014-02-05 2015-08-13 Kashiv Pharma Llc Formulations de medicament resistantes aux abus avec protection integree contre le surdosage
JP6510628B2 (ja) 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
WO2015173195A1 (fr) 2014-05-12 2015-11-19 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
PL3164117T3 (pl) 2014-07-03 2024-03-11 SpecGx LLC Preparaty zapewniające natychmiastowe uwalnianie i powstrzymujące przed nadużywaniem, zawierające polisacharydy inne niż celuloza
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP5888387B1 (ja) * 2014-10-22 2016-03-22 ミツミ電機株式会社 電池保護回路及び電池保護装置、並びに電池パック
WO2016170093A1 (fr) 2015-04-24 2016-10-27 Grünenthal GmbH Combinaison à dose fixe inaltérable présentant une libération rapide de deux médicaments de particules et d'une matrice
BR112017022856A2 (pt) 2015-04-24 2018-07-17 Gruenenthal Gmbh combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
US20160310428A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
WO2016170097A1 (fr) 2015-04-24 2016-10-27 Grünenthal GmbH Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant.
WO2017040607A1 (fr) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Procédés et compositions pour la libération auto-régulée d'un ingrédient pharmaceutique actif
CA2998259A1 (fr) 2015-09-10 2017-03-16 Grunenthal Gmbh Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
CA3000418A1 (fr) * 2015-09-30 2017-04-06 Kashiv Pharma Llc Formulation de medicament a liberation immediate de dissuasion d'abus et anti-surdose
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US20180303757A1 (en) * 2015-10-23 2018-10-25 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
JP2019504072A (ja) * 2016-02-08 2019-02-14 スペックジーエックス エルエルシー 徐放性及び濫用抑止特性を有するグルコマンナン含有医薬組成物
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
US20170296476A1 (en) 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
AU2017307235A1 (en) 2016-08-01 2019-01-31 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polysaccharide
JP2019524761A (ja) 2016-08-12 2019-09-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エフェドリン及びその誘導体の改変防止製剤
DE202016105585U1 (de) * 2016-10-06 2017-01-23 L.B. Bohle Maschinen + Verfahren Gmbh Anlage zur Herstellung pharmazeutischer Tabletten
USD857156S1 (en) * 2016-11-02 2019-08-20 Innovative Water Care, Llc Chemical tablet for aquatic systems
EP3554548A4 (fr) 2016-12-19 2020-08-19 The Regents of The University of California Formulations de pilules non broyables
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019003062A1 (fr) * 2017-06-29 2019-01-03 Zenvision Pharma Llp Forme galénique inviolable comprenant un agent pharmaceutiquement actif
EP4480495A3 (fr) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Capsule a double forme posologique pour libération et procédés, dispositifs et systèmes pour la produire
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3078272A1 (fr) 2017-10-13 2019-04-18 Grunenthal Gmbh Formes posologiques a liberation modifiee, dissuasives d'abus
CA3075292A1 (fr) * 2017-10-20 2019-04-25 Purdue Pharma L.P. Formes posologiques pharmaceutiques
US12161754B2 (en) 2017-12-20 2024-12-10 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
TW202002957A (zh) 2018-02-09 2020-01-16 德商歌林達有限公司 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物
EP3755785B1 (fr) 2018-02-22 2026-03-18 The Procter & Gamble Company Procédés de fabrication d'articles de dose unitaire
CN115532201A (zh) * 2018-06-21 2022-12-30 巴泰勒纪念研究所 增强型微通道或中通道装置及其增材制造方法
CA3103440A1 (fr) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Procede de traitement d'un trouble depressif majeur
BR112021004213A2 (pt) * 2018-09-06 2021-05-25 Fachhochschule Nordwestschweiz forma de dosagem de formulação farmacêutica e método para preparar uma forma de dosagem de formulação farmacêutica
WO2020068510A1 (fr) 2018-09-25 2020-04-02 SpecGx LLC Formes posologiques de capsules à libération immédiate anti-abus
WO2020070706A1 (fr) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Régime posologique d'eskétamine pour le traitement d'un trouble dépressif majeur
WO2020070547A1 (fr) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Régime posologique d'eskétamine pour le traitement d'un trouble dépressif majeur
WO2020075134A1 (fr) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Eskétamine pour une utilisation dans le traitement d'un trouble dépressif majeur
WO2020079699A1 (fr) * 2018-10-16 2020-04-23 M.O Advanced Technologies (Moat) Ltd Appareil et procédé permettant de prédire une propension de défauts de comprimé
CN111251521B (zh) * 2018-12-03 2022-07-22 沈欣 液态珠丸的制造方法
EP3698776A1 (fr) 2019-02-19 2020-08-26 Grünenthal GmbH Forme posologique inviolable à libération immédiate et résistance à l'extraction par solvant
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
AU2020347662B2 (en) * 2019-09-13 2026-07-09 Meiji Co., Ltd. Solid food and solid milk
CN110946086B (zh) * 2019-12-04 2023-05-12 北京猫猫狗狗科技有限公司 一种下料装置以及下料控制方法
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2021137147A1 (fr) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Régime posologique à base d'eskétamine pour le traitement d'un trouble dépressif majeur
WO2021146215A1 (fr) 2020-01-13 2021-07-22 Durect Corporation Systèmes d'administration de médicament à libération prolongée avec impuretés réduites et procédés associés
USD943706S1 (en) * 2020-06-10 2022-02-15 Emily Florence Johns Shower steamer
CA3203561A1 (fr) 2021-01-12 2022-07-21 Adrian Neil Verity Systemes d'administration de medicament a liberation prolongee et procedes associes
CN114659554B (zh) * 2022-03-01 2023-04-25 安徽农业大学 一种生物质颗粒机故障诊断方法
US20250082587A1 (en) 2023-09-12 2025-03-13 Clexio Biosciences Ltd. Method Of Treating Major Depressive Disorder

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1485673A (en) 1924-03-04 Ministrator
US1468805A (en) 1923-09-25 Htabtin ereund
US1479293A (en) 1924-01-01 Hiabtor fbettlid
US636438A (en) 1899-02-08 1899-11-07 Charles H Lovejoy Molder's chaplet.
US2654756A (en) 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3097144A (en) 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US3806603A (en) 1969-10-13 1974-04-23 W Gaunt Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
US3885027A (en) 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3966747A (en) 1972-10-26 1976-06-29 Bristol-Myers Company 9-Hydroxy-6,7-benzomorphans
US3888027A (en) 1973-07-30 1975-06-10 Kennametal Inc Arrangement for enhancing blade life
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3941865A (en) 1973-12-10 1976-03-02 Union Carbide Corporation Extrusion of ethylene oxide resins
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
GB1598458A (en) 1977-04-01 1981-09-23 Hoechst Uk Ltd Tableting of microcapsules
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4211681A (en) 1978-08-16 1980-07-08 Union Carbide Corporation Poly(ethylene oxide) compositions
CA1146866A (fr) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
DE3002664C2 (de) 1980-01-25 1989-05-18 Titmus Eurocon Kontaktlinsen Gmbh & Co Kg, 8750 Aschaffenburg Weiche Kontaktlinse
IL70071A (en) 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4501828A (en) 1983-01-20 1985-02-26 General Technology Applications,Inc. Dissolving water soluble polymers
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
FR2557459B1 (fr) 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
AU592065B2 (en) 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4616644A (en) 1985-06-14 1986-10-14 Johnson & Johnson Products, Inc. Hemostatic adhesive bandage
US4774092A (en) 1985-06-24 1988-09-27 Ici Australia Limited Ingestible capsules
US4619988A (en) 1985-06-26 1986-10-28 Allied Corporation High strength and high tensile modulus fibers or poly(ethylene oxide)
EP0328775B1 (fr) 1985-06-28 1993-10-20 Carrington Laboratories, Inc. Procédé de préparation de produits d'aloès, produits et compositions fabriqués selon lesdits procédés
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
DE3689650T2 (de) 1985-12-17 1994-05-26 United States Surgical Corp Bioresorbierbare Polymere von hohem Molekulargewicht und Implantate davon.
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
WO1988003408A1 (fr) 1986-11-10 1988-05-19 Biopure Corporation Succedane du sang semi-synthetique extra pur
DE3643789A1 (de) 1986-12-20 1988-06-30 Bayer Ag Thermoplastisch verarbeitbare, im wesentlichen lineare poly-(alpha)-aryl-olefin/polyurethan-blockcopolymere, verfahren zu deren herstellung und deren verwendung
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5139790A (en) 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5051222A (en) 1989-09-01 1991-09-24 Air Products And Chemicals, Inc. Method for making extrudable polyvinyl alcohol compositions
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5200197A (en) 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
FR2664851B1 (fr) 1990-07-20 1992-10-16 Oreal Procede de compactage d'un melange pulverulent permettant d'obtenir un produit compact absorbant ou partiellement delitable et produit obtenu par ce procede.
SE9003904D0 (sv) 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
WO1993006723A1 (fr) 1991-10-04 1993-04-15 Olin Corporation Comprime fongicide
AU3070892A (en) 1991-11-12 1993-06-15 Nepera, Inc. Adhesive hydrogels having extended use lives and process for the preparation of same
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
EP0615438B1 (fr) 1991-12-05 1996-07-24 Mallinckrodt Veterinary, Inc. Matrice en glucide transparent servant la liberation prolongee d'un agent therapeutique
SG43179A1 (en) 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
CA2117351C (fr) 1992-01-13 1998-03-03 Julian Belknap Lo Methode de fabrication permettant d'accroitre la durete des comprimes
US5393528A (en) 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR100355130B1 (ko) 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
AU679937B2 (en) 1992-11-18 1997-07-17 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
FR2701152B1 (fr) 1993-02-03 1995-03-10 Digipress Sa Procédé de fabrication d'un disque maître pour la réalisation d'une matrice de pressage notamment de disques optiques, matrice de pressage obtenue par ce procédé et disque optique obtenu à partir de cette matrice de pressage.
DE4309528C2 (de) 1993-03-24 1998-05-20 Doxa Gmbh Folie oder Folienschlauch aus Casein, Verfahren zu deren Herstellung und deren Verwendung
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
EP1442745A1 (fr) 1993-10-07 2004-08-04 Euro-Celtique Compositions d'opioides pour administration orale ayant un effet prolongé
US5776146A (en) 1993-10-20 1998-07-07 Applied Medical Resources Laparoscopic surgical clamp
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
EP0654263B1 (fr) 1993-11-23 2002-01-23 Euro-Celtique S.A. Procédé pour la préparation d'une composition pharmaceutique à libération prolongée
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
DE69530973T2 (de) 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen
EP0744940B1 (fr) 1994-02-17 1998-11-11 MODI, Pankaj Medicaments, vaccins et hormones incorpores dans des microspheres recouvertes de polylactides
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE69524214T3 (de) 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
CA2130410C (fr) 1994-08-18 2001-12-04 Albert John Kerklaan Plot de connexion retractable
SE502132C2 (sv) 1994-08-23 1995-08-28 Ecept Ab Gravstensfäste
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5516808A (en) 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4446470A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
ATE214596T1 (de) 1995-04-14 2002-04-15 Pharma Pass Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19547766A1 (de) 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
JP2000517287A (ja) 1996-03-11 2000-12-26 イーライ・リリー・アンド・カンパニー 物質乱用の処置方法
PT914097E (pt) 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US20020114838A1 (en) 1996-04-05 2002-08-22 Ayer Atul D. Uniform drug delivery therapy
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
EP0894010B1 (fr) 1996-04-10 2003-07-02 Warner-Lambert Company LLC Denaturants pour sels d'amine sympathomimetiques
US5886164A (en) 1996-04-15 1999-03-23 Zeneca Limited DNA encoding enzymes related to ethylene biosynthesis and ripening from banana
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
WO1997045091A2 (fr) 1996-05-31 1997-12-04 Euro-Celtique, S.A. Formulations d'oxycodone a liberation prolongee sans effet sur l'etat alimente/a jeun
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
US5730564A (en) 1996-07-24 1998-03-24 Illinois Tool Works Inc. Cargo load supporting air bag having inflation indicating means, and method of determining proper inflation for spaced loads
DE19630236A1 (de) 1996-07-26 1998-01-29 Wolff Walsrode Ag Biaxial gereckte, biologisch abbaubare und kompostierbare Wursthülle
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
BE1010353A5 (fr) 1996-08-14 1998-06-02 Boss Pharmaceuticals Ag Procede pour la fabrication de produits pharmaceutiques, dispositif pour un tel procede et produits pharmaceutiques ainsi obtenus.
EP0950689B1 (fr) 1996-11-05 2004-10-06 NOVAMONT S.p.A. Compositions polymériques biodégradables contenant de l'amidon et un polymère thermoplastique
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
FR2761605B1 (fr) 1997-04-07 2001-02-23 Prographarm Lab Forme pharmaceutique multiparticulaire, ses particules constitutives, procede et installation pour leur fabrication
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
IL121038A0 (en) 1997-06-09 1997-11-20 Technion Res & Dev Foundation A pharmaceutical composition for lowering glucose level in blood
DE19724181A1 (de) 1997-06-09 1998-12-10 Bayer Ag Multiple-unit-retard-Zubereitungen und Verfahren zu ihrer Herstellung
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
US6306438B1 (en) 1997-07-02 2001-10-23 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
WO1999016642A1 (fr) 1997-09-26 1999-04-08 Magna Interior Systems Inc. Ensemble de fixation permettant d'assembler deux panneaux de structure interieurs
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
DE59803468D1 (de) 1997-11-28 2002-04-25 Knoll Ag Verfahren zur herstellung von lösungsmittelfreien nicht-kristallinen biologisch aktiven substanzen
DE19753534A1 (de) 1997-12-03 1999-06-10 Bayer Ag Schnell kristallisierende, biologisch abbaubare Polyesteramide
GB9726365D0 (en) 1997-12-13 1998-02-11 Ciba Sc Holding Ag Compounds
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
NZ504834A (en) 1997-12-22 2001-12-21 Schering Corp Tricyclic amide molecular dispersion composition with enhanced bioavailability
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
DE19800698A1 (de) 1998-01-10 1999-07-15 Bayer Ag Biologisch abbaubare Polyesteramide mit blockartig aufgebauten Polyester- und Polyamid-Segmenten
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
DE69918233T2 (de) 1998-03-05 2005-02-24 Mitsui Chemicals, Inc. Polymilchsäure zusammensetzung und daraus hergestellter film
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6852337B2 (en) 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
DE19822979A1 (de) 1998-05-25 1999-12-02 Kalle Nalo Gmbh & Co Kg Folie mit Stärke oder Stärkederivaten und Polyesterurethanen sowie Verfahren zu ihrer Herstellung
EP0974343B1 (fr) 1998-07-22 2004-09-29 Pharma Pass II LLC Procédé de préparation d'une composition solide contentant du metoprolol
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
DE19838636A1 (de) 1998-08-26 2000-03-02 Basf Ag Carotinoid-Formulierungen, enthaltend ein Gemisch aus beta-Carotin, Lycopin und Lutein
DE19855440A1 (de) 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
IE981008A1 (en) 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
EP1005863A1 (fr) 1998-12-04 2000-06-07 Synthelabo Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
US6451604B1 (en) 1999-06-04 2002-09-17 Genesis Research & Development Corporation Limited Compositions affecting programmed cell death and their use in the modification of forestry plant development
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6403703B1 (en) 1999-08-27 2002-06-11 Rohm And Haas Company Polymeric compositions from acrylic and unsaturated carboxyl monomers
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
CA2388560A1 (fr) 1999-08-31 2001-03-08 Grunenthal Gmbh Forme d'administration a action retardee contenant du saccharinate de tramadol
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6491683B1 (en) 1999-09-07 2002-12-10 Alza Corporation Osmotic dosage form composed of an extruded polymer tube form
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
DE19960494A1 (de) 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
WO2001045644A2 (fr) 1999-12-23 2001-06-28 Combe International Ltd. Dispositif a resine de scellement et procede de fabrication
US6630086B1 (en) 1999-12-30 2003-10-07 Ethicon, Inc. Gas assist molding of one-piece catheters
ECSP003314A (es) 2000-01-11 2000-03-22 Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
SI2283842T1 (sl) 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
US6277409B1 (en) 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
DE10025947A1 (de) 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination enthaltend Montirelin und eine Verbindung mit opioider Wirksamkeit
DE10025948A1 (de) 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
US20030194748A1 (en) 2000-05-29 2003-10-16 Tohru Nagasaki Method for labeling with tritium
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10036400A1 (de) 2000-07-26 2002-06-06 Mitsubishi Polyester Film Gmbh Weiße, biaxial orientierte Polyesterfolie
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AU2001294902A1 (en) 2000-09-28 2002-04-08 The Dow Chemical Company Polymer composite structures useful for controlled release systems
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1387673B1 (fr) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
ATE345112T1 (de) 2001-05-11 2006-12-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
US7968119B2 (en) 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
DK1404331T3 (da) 2001-07-06 2008-01-28 Penwest Pharmaceuticals Co Sustained release-formuleringer af oxymorphon
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
AU2002319774B2 (en) 2001-08-06 2005-04-21 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
IL160217A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Compositions and methods to prevent abuse of opioids
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AU2002321879A1 (en) 2001-08-06 2003-03-03 Thomas Gruber Pharmaceutical formulation containing dye
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030069318A1 (en) 2001-08-21 2003-04-10 Wenbin Dang Salts of analgesic substances in oil, and methods of making and using the same
US6691698B2 (en) 2001-09-14 2004-02-17 Fmc Technologies Inc. Cooking oven having curved heat exchanger
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme de liberation a base de polymere
WO2003028698A2 (fr) 2001-09-26 2003-04-10 Steffens Klaus-Juergen Procede et dispositif de production de granules comprenant au moins un principe actif pharmaceutique
US20030229158A1 (en) 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
MXPA04002973A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (fr) 2001-10-25 2003-04-25 Depomed, Inc. Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
FR2833838B1 (fr) 2001-12-21 2005-09-16 Ellipse Pharmaceuticals Procede de fabrication d'un comprime incluant un analgesique de type morphinique et comprime obtenu
US6938129B2 (en) 2001-12-31 2005-08-30 Intel Corporation Distributed memory module cache
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
AU2003211146B2 (en) 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
GB0204772D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
US20030181882A1 (en) 2002-03-22 2003-09-25 Yasuo Toyoshima Absorbent article
DE10217232B4 (de) 2002-04-18 2004-08-19 Ticona Gmbh Verfahren zur Herstellung gefüllter Granulate aus Polyethylenen hohen bzw. ultrahohen Molekulargewichts
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
MXPA04010769A (es) 2002-04-29 2005-07-05 Alza Corp Metodos y formas de dosificacion para suministro controlado de oxicodona.
AU2003234395B2 (en) 2002-05-13 2008-01-24 Endo Pharmaceuticals Inc. Abuse-resistant opioid solid dosage form
WO2003097608A2 (fr) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Composes opioides et de type opioide et leurs utilisations
CA2487786A1 (fr) 2002-05-31 2003-12-11 Alza Corporation Formes galeniques et compositions d'administration osmotique de diverses posologies de l'oxycodone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250083A1 (de) 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
WO2004004693A1 (fr) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Compositions pharmaceutiques empechant la consommation abusive d'opioides et d'autres drogues
US6853758B2 (en) 2002-07-12 2005-02-08 Optimer Photonics, Inc. Scheme for controlling polarization in waveguides
US20040011806A1 (en) 2002-07-17 2004-01-22 Luciano Packaging Technologies, Inc. Tablet filler device with star wheel
EP1526843A1 (fr) 2002-07-25 2005-05-04 Pharmacia Corporation Procede de preparation de formes de dosage solides enrobees dans deux couches constituees d'un polymere insoluble dans l'eau et d'un faconneur de pores hydrosoluble
EP1537118A1 (fr) 2002-08-15 2005-06-08 Noramco, Inc. Polymorhes d'oxycodone-hydrochlorure
JP4195447B2 (ja) 2002-09-20 2008-12-10 エフ エム シー コーポレーション ミクロ結晶性セルロースを含有する化粧品用組成物
JP5189242B2 (ja) 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
CA2500311A1 (fr) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Formes de dosage a liberation modifiee
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
DE10250088A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US7093059B2 (en) 2002-12-31 2006-08-15 Intel Corporation Read-write switching method for a memory controller
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
JP5501553B2 (ja) 2003-04-21 2014-05-21 ユーロ−セルティーク エス．エイ． 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
BRPI0409945A (pt) 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
EP1624859A4 (fr) 2003-05-06 2010-06-23 Bpsi Holdings Inc Procede de preparation de compositions thermoformees contenant des liants de polymere acrylique, des posologies pharmaceutiques et leurs procedes de preparation
US20040241234A1 (en) 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
US6864370B1 (en) 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050031655A1 (en) 2003-08-04 2005-02-10 Schering Plough Healthcare Products, Inc. Emulsion composition
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PT1842533E (pt) 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
FR2858749B1 (fr) 2003-08-14 2006-03-17 Marcel Legris Ruche permettant a l'abeille et a l'apiculteur de lutter radicalement contre le varroa jacobsoni tout en ameliorant la production de miel
DE602004032149D1 (de) * 2003-09-26 2011-05-19 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
WO2005034859A2 (fr) 2003-10-03 2005-04-21 Elite Laboratories Inc. Formulations d'opioides a liberation prolongee et methode d'utilisation des formulations
KR20060108690A (ko) 2003-10-29 2006-10-18 알자 코포레이션 1일 1회 경구용의 서방성 옥시코돈 제형
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20090233272A1 (en) 2003-12-23 2009-09-17 Autogenomics, Inc. Multiplexed Nucleic Acid Analysis with High Specificity
AU2004314224A1 (en) 2004-01-23 2005-08-04 Antoine Sakellarides Shock absorbing system for rowing boat oarlock
WO2005079752A2 (fr) 2004-02-11 2005-09-01 Rubicon Research Private Limited Compositions pharmaceutiques a liberation controlee presentant une meilleure biodisponibilite
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403760D0 (en) 2004-02-20 2004-03-24 Clements Paul Digging implement
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
DK1729730T3 (da) * 2004-03-30 2009-03-23 Euro Celtique Sa Manipulationssikker doseringsform, der omfatter et adsorberende stof og et kontramiddel
PL1740156T3 (pl) * 2004-04-22 2011-12-30 Gruenenthal Gmbh Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
JP2006002884A (ja) * 2004-06-18 2006-01-05 Mitsubishi Plastics Ind Ltd 連結具
JP2006002886A (ja) * 2004-06-18 2006-01-05 Noriatsu Kojima 排水管
WO2006002286A1 (fr) * 2004-06-22 2006-01-05 Magna International Inc. Moulage d'etancheite d'automobile
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
PL1765298T3 (pl) 2004-07-01 2013-01-31 Gruenenthal Gmbh Sposób wytwarzania stałej postaci dawkowania, która jest zabezpieczona przez nadużywaniem, wykorzystujący wytłaczarkę z przekładnią planetarną
AR053304A1 (es) 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
CA2572491A1 (fr) 2004-07-01 2006-01-12 Gruenenthal Gmbh Forme posologique anti-abus pour administration par voie orale
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
KR100905511B1 (ko) 2005-01-28 2009-07-01 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
US20080274183A1 (en) 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
BRPI0612802A2 (pt) 2005-07-07 2010-11-30 Farnam Co Inc composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US7778314B2 (en) 2006-05-04 2010-08-17 Texas Instruments Incorporated Apparatus for and method of far-end crosstalk (FEXT) detection and estimation
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CN101652370A (zh) 2006-12-04 2010-02-17 诺拉姆科有限公司 制备14-羟基可待因酮水平减少的羟考酮的方法
EP2117518A2 (fr) 2007-01-12 2009-11-18 Wyeth a Corporation of the State of Delaware Composition de type comprimé-dans-comprimé
EP2104493A2 (fr) 2007-01-16 2009-09-30 Egalet A/S Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
WO2009114648A1 (fr) 2008-03-11 2009-09-17 Depomed Inc. Formes médicamenteuses à libération étendue de rétention gastrique comprenant des combinaisons d'un analgésique non opioïde et d'un analgésique opioïde
WO2009114646A2 (fr) 2008-03-11 2009-09-17 Robe Lighting Inc. Luminaires à réseau de del
US8671872B2 (en) 2009-02-16 2014-03-18 Thomas Engineering Inc. Production coater with exchangeable drums
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
US9492492B2 (en) * 2010-12-17 2016-11-15 Johnson & Johnson Consumer Inc. Compositions comprising Lilium martagon extracts and uses thereof
PL2826467T3 (pl) * 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
US9846413B2 (en) * 2011-09-08 2017-12-19 Fire Avert, Llc. Safety shut-off device and method of use
US10764498B2 (en) * 2017-03-22 2020-09-01 Canon Kabushiki Kaisha Image processing apparatus, method of controlling the same, and storage medium
US10764499B2 (en) * 2017-06-16 2020-09-01 Microsoft Technology Licensing, Llc Motion blur detection
JP7335870B2 (ja) * 2017-08-31 2023-08-30 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形
CA3075292A1 (fr) * 2017-10-20 2019-04-25 Purdue Pharma L.P. Formes posologiques pharmaceutiques

Also Published As

Publication number Publication date
US20210169810A1 (en) 2021-06-10
IL241121A0 (en) 2015-11-30
US9492390B2 (en) 2016-11-15
DK2292230T3 (da) 2012-08-20
US20150037413A1 (en) 2015-02-05
SI2384754T1 (sl) 2013-07-31
US9775809B2 (en) 2017-10-03
US8808741B2 (en) 2014-08-19
KR20090045381A (ko) 2009-05-07
HK1138498A1 (en) 2010-08-27
SI2080514T1 (sl) 2011-05-31
US20170319496A1 (en) 2017-11-09
IL217792A (en) 2015-09-24
PT2292229E (pt) 2012-08-28
EP2082742A1 (fr) 2009-07-29
US11964056B1 (en) 2024-04-23
US20230310326A1 (en) 2023-10-05
US9775811B2 (en) 2017-10-03
KR101496510B1 (ko) 2015-03-03
US8846086B2 (en) 2014-09-30
PT2311459E (pt) 2012-09-26
US20130251801A1 (en) 2013-09-26
SI2082742T1 (sl) 2011-03-31
US20210000747A1 (en) 2021-01-07
US20170128375A1 (en) 2017-05-11
US11826472B2 (en) 2023-11-28
US20240408024A1 (en) 2024-12-12
ES2411696T3 (es) 2013-07-08
JO3323B1 (ar) 2019-03-13
CA2707204C (fr) 2015-06-23
AT11571U1 (de) 2011-01-15
PT2070538E (pt) 2011-03-02
CN102688213A (zh) 2012-09-26
CA2661573A1 (fr) 2008-02-28
US20190000767A1 (en) 2019-01-03
US9492391B2 (en) 2016-11-15
US20130251799A1 (en) 2013-09-26
US20210000748A1 (en) 2021-01-07
KR20140049085A (ko) 2014-04-24
EA200900343A1 (ru) 2009-08-28
MY146650A (en) 2012-09-14
PL2292230T3 (pl) 2012-10-31
ME01064B (fr) 2012-10-20
US10076498B2 (en) 2018-09-18
US20170319491A1 (en) 2017-11-09
US9763886B2 (en) 2017-09-19
US9492393B2 (en) 2016-11-15
US11304909B2 (en) 2022-04-19
PL2384754T3 (pl) 2013-12-31
KR101787605B1 (ko) 2017-10-19
US12246094B2 (en) 2025-03-11
SI1897545T1 (sl) 2010-01-29
US8815289B2 (en) 2014-08-26
CL2014001029A1 (es) 2014-09-12
PT1897545E (pt) 2009-12-16
US20170128374A1 (en) 2017-05-11
PL2080514T3 (pl) 2011-09-30
ES2358066T3 (es) 2011-05-05
HK1165318A1 (en) 2012-10-05
DOP2009000026A (es) 2009-07-15
US20130259940A1 (en) 2013-10-03
US20170319498A1 (en) 2017-11-09
US20170319489A1 (en) 2017-11-09
EP2384754A1 (fr) 2011-11-09
RS52463B (sr) 2013-02-28
PT2292230E (pt) 2012-08-28
AR062511A1 (es) 2008-11-12
US20180153814A1 (en) 2018-06-07
US20170319497A1 (en) 2017-11-09
US11938225B2 (en) 2024-03-26
JP5642736B2 (ja) 2014-12-17
ATE444070T1 (de) 2009-10-15
US8894988B2 (en) 2014-11-25
RS52813B (sr) 2013-10-31
SI2399579T1 (sl) 2013-07-31
CN102688241B (zh) 2017-04-12
PL2343071T3 (pl) 2013-12-31
US20230270684A1 (en) 2023-08-31
US20130259938A1 (en) 2013-10-03
CY1111887T1 (el) 2015-11-04
MY161079A (en) 2017-04-14
NZ597760A (en) 2013-04-26
IN2015DN01813A (fr) 2015-07-10
ME01255B (fr) 2013-06-20
EP2070538A1 (fr) 2009-06-17
EP2080514A1 (fr) 2009-07-22
HRP20130444T1 (en) 2013-06-30
DE602007012747D1 (de) 2011-04-07
ME01187B (fr) 2011-10-31
EP2343071A1 (fr) 2011-07-13
KR20120105566A (ko) 2012-09-25
CN105213345B (zh) 2019-04-19
TN2009000059A1 (fr) 2010-08-19
US20150335583A1 (en) 2015-11-26
US9084816B2 (en) 2015-07-21
US9101661B2 (en) 2015-08-11
US20170319495A1 (en) 2017-11-09
ZA200900755B (en) 2009-12-30
IL241122A0 (en) 2015-11-30
BRPI0714539B8 (pt) 2021-05-25
JP2010501543A (ja) 2010-01-21
ES2334466T3 (es) 2010-03-10
US20090081290A1 (en) 2009-03-26
ES2417335T3 (es) 2013-08-07
US20140031381A1 (en) 2014-01-30
BRPI0714539A2 (pt) 2014-02-25
US20130260015A1 (en) 2013-10-03
PL2292229T3 (pl) 2012-10-31
ES2388615T3 (es) 2012-10-17
TW200824722A (en) 2008-06-16
CN102657630B (zh) 2014-10-01
IL197214A (en) 2015-09-24
US20130251800A1 (en) 2013-09-26
JP2012136543A (ja) 2012-07-19
US20150265599A1 (en) 2015-09-24
US20170319493A1 (en) 2017-11-09
US11904055B2 (en) 2024-02-20
US20140030327A1 (en) 2014-01-30
SI2292230T1 (sl) 2012-09-28
US9763933B2 (en) 2017-09-19
SI2311459T1 (sl) 2012-10-30
DK2399580T3 (da) 2013-06-24
PL2082742T3 (pl) 2011-05-31
ES2357376T3 (es) 2011-04-25
CN102657630A (zh) 2012-09-12
EP2080514B1 (fr) 2011-02-23
HRP20130434T1 (en) 2013-06-30
US9770417B2 (en) 2017-09-26
HRP20110147T1 (hr) 2011-04-30
DK2311459T3 (da) 2012-09-10
US20150265600A1 (en) 2015-09-24
CY1113220T1 (el) 2016-04-13
US9095615B2 (en) 2015-08-04
PE20080765A1 (es) 2008-06-13
ME01580B (me) 2014-09-20
US8821929B2 (en) 2014-09-02
BRPI0714539B1 (pt) 2020-11-24
IL217790A0 (en) 2012-03-29
US8911719B2 (en) 2014-12-16
SI2292229T1 (en) 2012-09-28
EP2292230B1 (fr) 2012-05-23
HK1118225A1 (en) 2009-02-06
HK1154788A1 (en) 2012-05-04
IL217794A0 (en) 2012-03-29
JP2015044834A (ja) 2015-03-12
EA018311B1 (ru) 2013-07-30
DE602007010963D1 (de) 2011-01-13
RS51591B (sr) 2011-08-31
IL217788A0 (en) 2012-03-29
CN101583360A (zh) 2009-11-18
EP2311459B1 (fr) 2012-06-27
US8894987B2 (en) 2014-11-25
HRP20120641T1 (hr) 2012-08-31
DK2070538T3 (da) 2011-03-21
ES2417334T3 (es) 2013-08-07
US20150335582A1 (en) 2015-11-26
US9775812B2 (en) 2017-10-03
DK2343071T3 (da) 2013-05-13
DK1897545T3 (da) 2010-02-08
PT2399579E (pt) 2013-06-24
US20170065527A1 (en) 2017-03-09
KR101649838B1 (ko) 2016-08-19
IL217792A0 (en) 2012-03-29
US20130251796A1 (en) 2013-09-26
CN107412179B (zh) 2020-09-04
CN103861111B (zh) 2017-04-12
EP2082742B1 (fr) 2010-12-01
ME01550B (me) 2014-04-20
US20170354607A1 (en) 2017-12-14
RS52401B (sr) 2013-02-28
US20130259939A1 (en) 2013-10-03
US20250082581A1 (en) 2025-03-13
US20250352480A1 (en) 2025-11-20
PE20150340A1 (es) 2015-02-28
EP2399580B1 (fr) 2013-04-03
US11304908B2 (en) 2022-04-19
DK2082742T3 (da) 2011-03-21
US20170319490A1 (en) 2017-11-09
KR20170118249A (ko) 2017-10-24
RS52402B (sr) 2013-02-28
CN102688241A (zh) 2012-09-26
EP2399579B9 (fr) 2013-07-24
CL2017000669A1 (es) 2017-11-10
US9492392B2 (en) 2016-11-15
PL2399579T3 (pl) 2013-12-31
JP5980881B2 (ja) 2016-08-31
NZ608651A (en) 2014-07-25
EP2311459A1 (fr) 2011-04-20
US20150028512A1 (en) 2015-01-29
US9545380B2 (en) 2017-01-17
GT200900023A (es) 2010-11-05
IL217791A0 (en) 2012-03-29
HRP20130539T1 (en) 2013-07-31
US20240226019A1 (en) 2024-07-11
CN103861111A (zh) 2014-06-18
CN105213345A (zh) 2016-01-06
UA96306C2 (ru) 2011-10-25
KR101455914B1 (ko) 2014-11-03
IL217787A0 (en) 2012-03-29
CL2007002485A1 (es) 2008-01-25
PE20091184A1 (es) 2009-08-03
US20170128440A1 (en) 2017-05-11
JP5373133B2 (ja) 2013-12-18
PL2311459T3 (pl) 2012-12-31
NZ574447A (en) 2012-04-27
EP2292230A1 (fr) 2011-03-09
JP2012229249A (ja) 2012-11-22
JP2012229250A (ja) 2012-11-22
US20170319488A1 (en) 2017-11-09
HK1133192A1 (en) 2010-03-19
IL197214A0 (en) 2009-12-24
CN101583360B (zh) 2014-02-26
HRP20130433T1 (en) 2013-06-30
SI2070538T1 (sl) 2011-03-31
CY1110573T1 (el) 2015-04-29
PT2343071E (pt) 2013-05-29
US9486413B2 (en) 2016-11-08
AR103463A2 (es) 2017-05-10
CA2661573C (fr) 2010-10-26
PE20191048A1 (es) 2019-08-06
US9486412B2 (en) 2016-11-08
BR122016004010B1 (pt) 2020-11-24
US20240115507A1 (en) 2024-04-11
US20170128372A1 (en) 2017-05-11
ES2361721T3 (es) 2011-06-21
US9770416B2 (en) 2017-09-26
HRP20120670T1 (hr) 2012-09-30
KR20150082669A (ko) 2015-07-15
DK2292229T3 (da) 2012-08-13
CY1113231T1 (el) 2016-04-13
CA2707204A1 (fr) 2008-02-28
HRP20120613T1 (hr) 2012-08-31
ATE499101T1 (de) 2011-03-15
RS52793B (sr) 2013-10-31
IL217789A0 (en) 2012-03-29
US9095614B2 (en) 2015-08-04
ME01339B (fr) 2013-12-20
EA201171403A1 (ru) 2012-05-30
IL217791A (en) 2015-09-24
HK1132189A1 (en) 2010-02-19
US9775810B2 (en) 2017-10-03
DOP2011000255A (es) 2011-10-15
PT2082742E (pt) 2011-03-02
ES2388591T3 (es) 2012-10-16
CN105267170A (zh) 2016-01-27
MX360849B (es) 2018-11-20
US20130251797A1 (en) 2013-09-26
DK2384754T3 (da) 2013-05-06
RS51678B (sr) 2011-10-31
MY153092A (en) 2014-12-31
EP1897545A1 (fr) 2008-03-12
IL241122B (en) 2019-05-30
CN102743355B (zh) 2014-12-24
KR101568100B1 (ko) 2015-11-12
RS51162B (sr) 2010-10-31
US20170319494A1 (en) 2017-11-09
AR109797A2 (es) 2019-01-23
US20210000749A1 (en) 2021-01-07
HK1246175A1 (zh) 2018-09-07
US20170348240A1 (en) 2017-12-07
MX2009002023A (es) 2009-03-05
PT2080514E (pt) 2011-05-24
US20130251798A1 (en) 2013-09-26
PL2399580T3 (pl) 2013-12-31
US20250073173A1 (en) 2025-03-06
EA201300465A1 (ru) 2013-08-30
HK1165317A1 (en) 2012-10-05
US20170246116A1 (en) 2017-08-31
AU2007287341A1 (en) 2008-02-28
US20150335584A1 (en) 2015-11-26
US20150335580A1 (en) 2015-11-26
KR20110119847A (ko) 2011-11-02
EP2070538B1 (fr) 2010-12-01
EP2292229A1 (fr) 2011-03-09
US11298322B2 (en) 2022-04-12
JP2012167102A (ja) 2012-09-06
TWI341213B (en) 2011-05-01
US20170128370A1 (en) 2017-05-11
AR109796A2 (es) 2019-01-23
SI2343071T1 (sl) 2013-07-31
HK1154491A1 (en) 2012-04-27
UA104745C2 (ru) 2014-03-11
HK1154789A1 (en) 2012-05-04
US20150037411A1 (en) 2015-02-05
GT200900023BA (es) 2018-09-28
ATE489953T1 (de) 2010-12-15
AU2007287341B2 (en) 2011-08-25
IL241121A (en) 2017-09-28
US20130251802A1 (en) 2013-09-26
EP1897545B1 (fr) 2009-09-30
EP2399579A1 (fr) 2011-12-28
KR20120105565A (ko) 2012-09-25
ME01482B (me) 2014-04-20
JP2016222698A (ja) 2016-12-28
JP5069300B2 (ja) 2012-11-07
PT2399580E (pt) 2013-07-05
EA023807B1 (ru) 2016-07-29
CR10691A (es) 2009-06-05
RS52798B (sr) 2013-10-31
HK1156845A1 (en) 2012-06-22
IL217794A (en) 2015-09-24
RS51664B (sr) 2011-10-31
US9775808B2 (en) 2017-10-03
US20170128373A1 (en) 2017-05-11
CO6160317A2 (es) 2010-05-20
US20170348241A1 (en) 2017-12-07
CY1111896T1 (el) 2015-11-04
KR20160099738A (ko) 2016-08-22
US8834925B2 (en) 2014-09-16
CY1113141T1 (el) 2016-04-13
EP2343071B1 (fr) 2013-03-20
EA031873B1 (ru) 2019-03-29
EP2292229B1 (fr) 2012-05-23
US9492389B2 (en) 2016-11-15
KR101514388B1 (ko) 2015-04-23
HK1165316A1 (en) 2012-10-05
US20140024669A1 (en) 2014-01-23
US20150037412A1 (en) 2015-02-05
ES2411695T3 (es) 2013-07-08
PE20140854A1 (es) 2014-07-19
JP6286491B2 (ja) 2018-02-28
HRP20090688T1 (hr) 2010-02-28
PL2070538T3 (pl) 2011-05-31
SA07280459B1 (ar) 2011-07-20
ES2390419T3 (es) 2012-11-12
US12396955B2 (en) 2025-08-26
US20150335585A1 (en) 2015-11-26
DK2080514T3 (da) 2011-05-16
EP2399579B1 (fr) 2013-04-03
CN102743355A (zh) 2012-10-24
US20250235407A1 (en) 2025-07-24
DK2399579T3 (da) 2013-06-17
JO2858B1 (en) 2015-03-15
SI2399580T1 (sl) 2013-07-31
RS52779B (sr) 2013-10-31
CY1111897T1 (el) 2015-11-04
KR101205579B1 (ko) 2012-11-28
DE202007011825U1 (de) 2008-04-30
US12280152B2 (en) 2025-04-22
PL1897545T3 (pl) 2010-02-26
US20150265601A1 (en) 2015-09-24
CN105267170B (zh) 2019-01-01
HRP20110130T1 (hr) 2011-03-31
US20170319492A1 (en) 2017-11-09
DE602007002596D1 (de) 2009-11-12
DE602007010974D1 (de) 2011-01-13
ATE489954T1 (de) 2010-12-15
US20230134700A1 (en) 2023-05-04
CN107412179A (zh) 2017-12-01
PT2384754E (pt) 2013-05-24
CR20140340A (es) 2014-10-16
EP2384754B1 (fr) 2013-03-20
HRP20110375T1 (hr) 2011-06-30
EP2399580A1 (fr) 2011-12-28
US20180153815A1 (en) 2018-06-07
US20170128371A1 (en) 2017-05-11
US20180369150A1 (en) 2018-12-27
US20170128369A1 (en) 2017-05-11
WO2008023261A1 (fr) 2008-02-28
JP2012236835A (ja) 2012-12-06
US10076499B2 (en) 2018-09-18
AP2009004770A0 (en) 2009-02-28
BR122016004010B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
HRP20120004T1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MA29734B1 (fr) Formes posologiques solides de valsartan et d'amlodipine et procede de preparation afferent
MA30807B1 (fr) Compositions pharmaceutiques.
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
JO2515B1 (en) Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it
MA34474B1 (fr) Agonistes de gpr40
PL415001A1 (pl) Kompozycje farmaceutyczne zawierające kwas mykofenolowy lub sól mykofenolanową
IL193252A0 (en) N-hydroxyacrylamide compounds
BRPI0509184A (pt) composições farmacêuticas
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
BRPI0519198A2 (pt) moduladores de delta-opiàide tricÍclicos
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
IL191670A0 (en) Compounds for the inhibition of apoptosis
BRPI0509014A (pt) comprimidos desintegráveis que compreendem licarbazepina
EA200900622A1 (ru) Фармацевтическая композиция, содержащая полиморфную форму 1 клопидогрела гидросульфата
EA201000118A1 (ru) Сублингвальные или трансбуккальные композиции, содержащие янтарную кислоту и предназначенные для лечения болезни альцгеймера
FR2898059B1 (fr) Composition phytohormonale contenant de la sauge
NO20044900L (no) Progestagene doseringsenheter
RU2008132511A (ru) Способ лечения гипертензивных внутримозговых кровоизлияний